Evidence map›Paper›PMID 36526666›Full record

ArticleScientific reports2022

Sleep and breast and prostate cancer risk in the MCC-Spain study.

Michelle C Turner, Esther Gracia-Lavedan, Kyriaki Papantoniou, Nuria Aragonés, Gemma Castaño-Vinyals, Trinidad Dierssen-Sotos, Pilar Amiano, Eva Ardanaz, Alba Marcos-Delgado, Ana Molina-Barceló and 9 more

Abstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Michelle C TurnerBarcelona Institute for Global Health (ISGlobal), Doctor Aiguader, 88, 08003, Barcelona, Spain. michelle.turner@isglobal.org.
Esther Gracia-LavedanBarcelona Institute for Global Health (ISGlobal), Doctor Aiguader, 88, 08003, Barcelona, Spain.
Kyriaki PapantoniouDepartment of Epidemiology, Center of Public Health, Medical University of Vienna, Vienna, Austria.
Nuria AragonésCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Gemma Castaño-VinyalsBarcelona Institute for Global Health (ISGlobal), Doctor Aiguader, 88, 08003, Barcelona, Spain.
Trinidad Dierssen-SotosCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Pilar AmianoCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Eva ArdanazCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Alba Marcos-DelgadoInstituto de Biomedicina, Universidad de León, León, Spain.
Ana Molina-BarcelóCancer and Public Health Area, FISABIO-Public Health, Valencia, Spain.
Juan AlguacilCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Yolanda BenaventeCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Thalia BelmonteIUOPA, University of Oviedo and ISPA (Health Research Institute of Asturias), Oviedo, Spain.
José J Jiménez-MoleónCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Rafael Marcos-GrageraCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Beatriz PérezNational Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.
Inés Gómez-AceboCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Marina PollánCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Manolis KogevinasBarcelona Institute for Global Health (ISGlobal), Doctor Aiguader, 88, 08003, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast and prostate cancers have been associated with circadian disruption. Some previous studies examined associations of sleep duration and breast or prostate cancer risk though findings remain inconsistent. This study examines associations of a range of detailed sleep characteristics and breast and prostate cancer risk in a large-scale population-based case-control study, MCC-Spain. A total of 1738 incident breast cancer cases, 1112 prostate cancer cases and frequency matched controls (n = 1910, and 1493 respectively) were recruited. Detailed data on habitual sleep duration, quality, timing, and daytime napping ("siesta") were collected at recruitment. Additional data on sleep habits during both the previous year and at age 40 years were also subsequently captured. Adjusted odds ratios (ORs) and 95% confidence intervals (CI) were estimated. There were no associations of habitual sleep duration (h), timing of sleep, or any or specific sleep problems, and either breast and prostate cancer risk. There was a significant positive association of ever taking habitual siestas at recruitment and breast cancer risk (OR = 1.22, 95% CI 1.06-1.42), which strengthened with increased frequency or duration. There were also significant positive associations observed for both breast and prostate cancer, among those reporting recent sleep problems, but not sleep problems at age 40 years, in a subsequent circadian questionnaire. Adverse associations with siesta and disturbed sleep during the previous year likely reflect symptoms of developing/diagnosed cancer and comorbidities. Overall, there was no clear association between various sleep characteristics and breast or prostate cancer risk observed.

Indexed as

Breast NeoplasmsProstatic NeoplasmsAdultCase-Control StudiesHumansMaleRisk FactorsSleepSpain

Identifiers

PMID36526666
PMCPMC9758125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.